Eastern European and Central Asian Community Advisory Board (EECA CAB) and ViiV Healthcare - meeting minutes
Apskatīt komentārus (0)
21.04.2013
EECA CAB believes that ViiVs policy on drug registration in several countries in the EECA region could jeopardize access to treatment; and ViiV should take steps towards registration of their products in the countries where they are not registered yet and can be delivered only through donor programs, thereby eliminating the risk of treatment interruption after the donors withdraw the programs.
EECA CAB believes that after the curtailing of GF programs in EECA region, ViiVs drugs should be available to governments for a price not higher than the price within the GF program.
EECA CAB believes that ViiV should include countries of EECA region into the list of countries covered by voluntary licenses in bilateral agreements with generic companies and in the agreements made with Medicines Patent Pool.
EECA CAB considers that in all the EECA countries hypersensitivity tests for abacavir-containing drugs and CCR5 tropism tests for maraviroc should be available at ViiVs cost for patients receiving treatment with the respective ViiVs products.
Read full minutes at http://itpcru.org/netcat_files/File/EECA_CAB_meeting_ViiV_Healthcare_07_02_2013_ENG_F.pdf
